Identification of tumor-associated peptides presented by hla molecules from colon carcinoma cells

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Stimulation or adoptive-transfer of tumor-specific T cells are, at present promising new lines in cancer immunotherapy. For melanomas, tumor-selective peptides presented by HLA-molecules to cytotoxic T cells (CTL) have been identified, first clinical trials being underway. For many other tumors including colorectalcarcinomas, relevant information is not yet available, although candidate antigens for tumor-specific immunity are known, including mutated-RAS. The objective of this proposal is to definitely identify HLA-class-one presented peptides of mutated-RAS and other tumor-associated proteins (ex: p53 CEA) by a purely biochemical approach. Large number of colorectal-carcinoma cells will be produced, either by in vitro culture or by expansion in nude mice of cell lines already established at INSERM U395. HLA-molecules will be precipitated and associated peptides will be extracted using procedures well established in Dr. Rammensee's group. Resulting peptide mixtures will be screened by mass-spectrometry for peptides conform with those predicted based on the protein sequence of the candidate antigens and allele-specific HLA motifs that have been determined in Dr. Rammensee's laboratory. Results are expected to give the basis for experimental immunotherapy of colorectal-carcinomas, using peptide specific CTL.

Original text from CORDIS.

Participants

• Eberhard-Karls-Universität Tübingen · TübingenCoordinatorGermany
• Not availableCity levelFrance

Links

• View on CORDIS